Optiver Holding
CRSP icon

Optiver Holding’s CRISPR Therapeutics CRSP Stock Holding History

Optiver Holding’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$16.1K Buy
338
+19
+6% +$1K ﹤0.01% 1137
2025
Q4 		$16.7K Sell
319
-185
-37% -$11.1K ﹤0.01% 1058
2025
Q3 		$32.7K Buy
504
+210
+71% +$12.1K ﹤0.01% 855
2025
Q2 		$14.3K Buy
+294
New +$11.4K ﹤0.01% 913

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GP
GSK plc London $599M AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Optiver Holding's CRSP Position: Q1 2026 in Review

Optiver Holding increased its CRISPR Therapeutics (CRSP) stake by 6% in Q1 2026, buying an estimated $1K and bringing the position to 338 shares worth $16.1K. The position accounts for ﹤0.01% of the portfolio, ranked #1137.

Optiver Holding first reported a position in CRSP in Q2 2025 and has held it in 4 quarters since. The position peaked at $32.7K in Q3 2025. 488 funds tracked by Wall St. Rank hold CRSP as of Q1 2026.

  • Optiver Holding held 338 shares of CRISPR Therapeutics worth $16.1K as of Q1 2026.
  • Optiver Holding bought 19 CRISPR Therapeutics shares in Q1 2026, an estimated $1K.
  • CRISPR Therapeutics made up ﹤0.01% of Optiver Holding's portfolio in Q1 2026, its #1137 holding.
  • Optiver Holding first reported a position in CRISPR Therapeutics in Q2 2025 and has held it in 4 quarters since.
  • Optiver Holding's CRISPR Therapeutics position peaked at $32.7K in Q3 2025.
  • 488 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q1 2026.

Based on Optiver Holding's 13F filing for Q1 2026, filed 15 May 2026.